drugset / Trial / NCT00819728

Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer

NCT00819728 ↗

Phase 2 Completed 35 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of the study is to determine the activity of the weekly combination of docetaxel (Taxotere) and irinotecan in terms of response rate in subjects with advanced, previously untreated, non-small cell lung cancer. It is also to determine the activity of this combination in terms of response duration, time to progression, median survival, overall survival, and percent one-year survival, as well as the side-effect and toxicity profile of weekly Taxotere and weekly irinotecan.

Timeline

Start
2000-06
Primary completion
—
Completion
2003-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 35 mg/m2 Intravenous
Subject Irinotecan Small molecule 50 mg/m2 Intravenous